<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="publisher-id">jdi</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>BlackWell Publishing Ltd</publisher-name><publisher-loc>Oxford, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25802726</article-id><article-id pub-id-type="pmc">4364853</article-id><article-id pub-id-type="doi">10.1111/jdi.12282</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Trial</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type&#x000a0;2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yokoh</surname><given-names>Hidetaka</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kobayashi</surname><given-names>Kazuki</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Yasunori</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Takemoto</surname><given-names>Minoru</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uchida</surname><given-names>Daigaku</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Kanatsuka</surname><given-names>Azuma</given-names></name><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kuribayashi</surname><given-names>Nobuichi</given-names></name><xref ref-type="aff" rid="au7">7</xref></contrib><contrib contrib-type="author"><name><surname>Terano</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="au8">8</xref></contrib><contrib contrib-type="author"><name><surname>Hashimoto</surname><given-names>Naotake</given-names></name><xref ref-type="aff" rid="au9">9</xref></contrib><contrib contrib-type="author"><name><surname>Sakurai</surname><given-names>Kenichi</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hanaoka</surname><given-names>Hideki</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ishikawa</surname><given-names>Ko</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Onishi</surname><given-names>Shunichiro</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yokote</surname><given-names>Koutaro</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><author-comment><p>on behalf of the SUCCESS Study Group</p></author-comment></contrib><aff id="au1"><label>1</label><institution>Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Diabetes, Metabolism and Endocrinology, Chiba University Hospital</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au3"><label>3</label><institution>Chiba University Hospital Clinical Research Center</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au4"><label>4</label><institution>Department of Regional Disaster Medicine, Chiba University Graduate School of Medicine</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au5"><label>5</label><institution>Hotaruno Central Clinic</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au6"><label>6</label><institution>Chiba Central Medical Center</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au7"><label>7</label><institution>Misaki Naika Clinic</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au8"><label>8</label><institution>Chiba Aoba Municipal Hospital</institution><addr-line>Chiba, Japan</addr-line></aff><aff id="au9"><label>9</label><institution>Tokyo Women's Medical University Yachiyo Medical Center</institution><addr-line>Chiba, Japan</addr-line></aff></contrib-group><author-notes><corresp id="cor1">
* <bold>Correspondence</bold> Koutaro Yokote, Tel.: +81-43-226-2089, Fax: +81-43-226-2095, E-mail address: <email>kyokote@faculty.chiba-u.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>24</day><month>9</month><year>2014</year></pub-date><volume>6</volume><issue>2</issue><fpage>182</fpage><lpage>191</lpage><history><date date-type="received"><day>06</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>31</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Authors. Journal of Diabetes Investigation published by Asian Association of the Study of Diabetes (AASD) and Wiley Publishing Asia Pty Ltd</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><license-p>This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license></permissions><abstract><sec><title>Aims/Introduction</title><p>To assess the efficacy and safety of sitagliptin compared with &#x003b1;-glucosidase inhibitors in Japanese patients with type&#x000a0;2 diabetes inadequately controlled by metformin or pioglitazone alone.</p></sec><sec><title>Materials and Methods</title><p>In the present multicenter, randomized, open-label, parallel-group, active-controlled, non-inferiority trial, 119 patients aged 20&#x02013;79&#x000a0;years with type&#x000a0;2 diabetes who had glycated hemoglobin 6.9&#x02013;8.8% on stable metformin (500&#x02013;1,500&#x000a0;mg/day) or pioglitazone (15&#x02013;30&#x000a0;mg/day) alone were randomly assigned (1:1) to receive the addition of sitagliptin (50&#x000a0;mg/day) or an &#x003b1;-glucosidase inhibitor (0.6&#x000a0;mg/day voglibose or 150&#x000a0;mg/day miglitol) for 24&#x000a0;weeks. The primary end-point was change in glycated hemoglobin from baseline to week&#x000a0;12. All data were analyzed according to the intention-to-treat principle.</p></sec><sec><title>Results</title><p>After 12&#x000a0;weeks, reductions in adjusted mean glycated hemoglobin from baseline were &#x02212;0.70% in sitagliptin and &#x02212;0.21% in the &#x003b1;-glucosidase inhibitor groups respectively; between-group difference was &#x02212;0.49% (95% confidence interval &#x02212;0.66 to &#x02212;0.32, <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001), meeting the predefined non-inferiority criterion (0.25%) and showing statistical significance. This statistical significance also continued after 24&#x000a0;weeks. Although sitagliptin did not affect bodyweight, &#x003b1;-glucosidase inhibitors decreased bodyweight significantly from baseline (&#x02212;0.39&#x000a0;kg; <italic>P</italic>&#x000a0;=&#x000a0;0.0079). Gastrointestinal disorders were significantly lower with sitagliptin than with an &#x003b1;-glucosidase inhibitor (6 [10.3%] patients vs 23 [39.7%]; <italic>P</italic>&#x000a0;=&#x000a0;0.0003). Minor hypoglycemia occurred in two patients (3.5%) in each group.</p></sec><sec><title>Conclusions</title><p>Sitagliptin showed greater efficacy and better tolerability than an &#x003b1;-glucosidase inhibitor when added to stable doses of metformin or pioglitazone. These findings support the use of sitagliptin in Japanese patients with type&#x000a0;2 diabetes inadequately controlled by insulin-sensitizing agents. This trial was registered with UMIN (no. 000004675).</p></sec></abstract><kwd-group><kwd>Alpha-glucosidase inhibitor</kwd><kwd>Combination drug therapy</kwd><kwd>Sitagliptin</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Type&#x000a0;2 diabetes accounts for approximately 90% of all cases of diabetes mellitus, and its incidence is rapidly increasing. Currently, approximately 366&#x000a0;million people worldwide have diabetes, and 552&#x000a0;million are expected to have diabetes by 2030<xref rid="b1" ref-type="bibr">1</xref>. Diabetes can lead to various vascular complications that contribute to mortality, reduced quality of life and excessive medical costs. To prevent diabetic vascular complications, achievement of optimal glycemic control (e.g., glycated hemoglobin [HbA1c]&#x000a0;&#x0003c;&#x000a0;7.0%) from an early stage of the disease is recommended<xref rid="b2" ref-type="bibr">2</xref>&#x02013;<xref rid="b4" ref-type="bibr">4</xref>. However, hypoglycemia and weight gain associated with tight glycemic control could have potentially negative effects on cardiovascular risk and mortality<xref rid="b5" ref-type="bibr">5</xref>.</p><p>The American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommend metformin as a first-line oral therapy for treatment of type&#x000a0;2 diabetes<xref rid="b6" ref-type="bibr">6</xref>. Metformin has a low hypoglycemia risk when used alone, and might reduce cardiovascular events<xref rid="b7" ref-type="bibr">7</xref>; thus, metformin is the most widely used drug in the treatment of type&#x000a0;2 diabetes. Pioglitazone, which activates peroxisome proliferator-activated receptor&#x000a0;&#x003b3; (PPAR&#x003b3;)<xref rid="b8" ref-type="bibr">8</xref>, also has a low risk of hypoglycemia with a beneficial effect on cardiovascular events, as shown in a large trial involving patients with overt macrovascular disease<xref rid="b9" ref-type="bibr">9</xref>. Both of these drugs are insulin-sensitizing agents, contribute to glycemic control and are widely used as an initial drug for treatment of diabetes in Japan. However, because type&#x000a0;2 diabetes is a progressive disease, most people eventually require additional treatment to achieve good glycemic control<xref rid="b10" ref-type="bibr">10</xref>, and especially, a choice of the second-line drug is very important to determine subsequent glycemic control.</p><p>Sitagliptin is a once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycemic control by preventing the rapid degradation of incretin hormones<xref rid="b11" ref-type="bibr">11</xref>. Sitagliptin is well-tolerated, and associated with a low risk of hypoglycemia and weight gain when used alone<xref rid="b12" ref-type="bibr">12</xref>&#x02013;<xref rid="b14" ref-type="bibr">14</xref>. In Japan, the most frequently used oral hypoglycemic agent had been sulfonylurea until the appearance of DPP-4 inhibitor<xref rid="b15" ref-type="bibr">15</xref>. As this relatively new agent is comparatively effective for Japanese patients, it has been becoming widely used in combination therapy as well as in monotherapy. In contrast, &#x003b1;-glucosidase inhibitors, which lower postprandial glucose excursions, have been widely used in Japan as first-line and combined drugs for a long time. Alpha-glucosidase inhibitors have shown clear efficacy and are relatively safe for patients with type&#x000a0;2 diabetes<xref rid="b16" ref-type="bibr">16</xref>, and the risk of hypoglycemia and weight gain is minimal, because they reduce oversecretion of insulin and consequently lighten the load of the pancreas. Furthermore, &#x003b1;-glucosidase inhibitors have been shown to reduce cardiovascular events in patients with type&#x000a0;2 diabetes as well as those with impaired glucose tolerance<xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b18" ref-type="bibr">18</xref>. In fact, in patients with impaired glucose tolerance, &#x003b1;-glucosidase inhibitors help prevent the development of type&#x000a0;2 diabetes<xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref>. Recently, Iwamoto <italic>et&#x000a0;al</italic>.<xref rid="b21" ref-type="bibr">21</xref> reported that greater efficacy and better tolerability of sitagliptin monotherapy than that of &#x003b1;-glucosidase inhibitor (voglibose) in Japanese patients with type&#x000a0;2 diabetes.</p><p>In Western countries, sitagliptin has been shown to be effective in combination with metformin or pioglitazone<xref rid="b22" ref-type="bibr">22</xref>&#x02013;<xref rid="b24" ref-type="bibr">24</xref>. However, in Asian patients with diabetes, the glucose-lowering effects, changes in insulin secretion and resistance, frequencies of hypoglycemia, and effects on bodyweight when sitagliptin is used in combination therapy have not been sufficiently documented. Therefore, in the present Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1 (SUCCESS-1) trial, focusing on the choice of the second-line drug, we aimed to assess the efficacy and safety of sitagliptin compared with an &#x003b1;-glucosidase inhibitor in Japanese patients with type&#x000a0;2 diabetes who were inadequately controlled by metformin or pioglitazone alone.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Design</title><p>The present multicenter, randomized, open-label, parallel-group, active-controlled, non-inferiority trial was carried out at 37 sites in Japan from January 2011 to September 2012. It included an initial observation period within 8&#x000a0;weeks followed by a 24-week treatment period (sitagliptin or &#x003b1;-glucosidase inhibitor) and, finally, 4&#x000a0;weeks of follow up to record any new adverse events. The present study was approved by the ethics committee at the each center and registered at <ext-link ext-link-type="uri" xlink:href="http://www.umin.ac.jp/ctr/">http://www.umin.ac.jp/ctr/</ext-link> (UMIN-ID: UMIN 000004675).</p></sec><sec sec-type="methods"><title>Participants</title><p>Eligible study participants were men and women aged 20&#x02013;79&#x000a0;years with type&#x000a0;2 diabetes receiving metformin (500&#x02013;1,500&#x000a0;mg/day) or pioglitazone (15&#x02013;30&#x000a0;mg/day) for 2&#x000a0;months or longer, and with a HbA1c level of 6.9&#x02013;8.8%. The main exclusion criteria were previous treatment with insulin or oral glucose-lowering drugs other than metformin or pioglitazone within the past 2&#x000a0;months; impaired renal function (serum creatinine &#x02265;133&#x000a0;&#x003bc;mol/L in men or &#x02265;115&#x000a0;&#x003bc;mol/L in women); or a diagnosis of stroke, myocardial infarction, or other severe cardiovascular complications requiring hospitalization within the past 6&#x000a0;months. All patients provided written informed consent.</p></sec><sec><title>Procedures and Randomization</title><p>Patients receiving metformin or pioglitazone entered an initial observation period within 8&#x000a0;weeks. At the end of the observation period, patients were randomly assigned to either 24&#x000a0;weeks of treatment with sitagliptin (50&#x000a0;mg once a day) or an &#x003b1;-glucosidase inhibitor (0.2&#x000a0;mg voglibose or 50&#x000a0;mg miglitol three times a day) added to ongoing metformin or pioglitazone (dose unchanged throughout the study) through a website using a minimization method<xref rid="b25" ref-type="bibr">25</xref> with biased-coin assignment balancing including age (&#x02265;65&#x000a0;years vs &#x0003c;65&#x000a0;years), sex and type of premedication (metformin vs pioglitazone).</p></sec><sec><title>Study End-Points</title><p>The primary efficacy end-point was change in HbA1c from baseline at week&#x000a0;12. Secondary end-points were change in HbA1c from baseline at week&#x000a0;24, proportion of participants reaching HbA1c targets of &#x0003c;7.0%, (as recommended by the ADA)<xref rid="b26" ref-type="bibr">26</xref> at week&#x000a0;12 and 24, changes from baseline at week&#x000a0;12 and 24 in fasting plasma glucose (FPG), glycoalbumin, 1,5-anhydroglucitol (1,5-AG), fasting insulin and C-peptide concentrations, plasma proinsulin/insulin ratio, homoeostasis model assessment of &#x003b2;-cell function (HOMA-&#x003b2;), homoeostasis model assessment of insulin resistance (HOMA-IR), fasting lipid profile, urinary biomarkers, bodyweight, blood pressure, and heart rate. Laboratory analyses were carried out by SRL Corporation (Tokyo, Japan).</p><p>Safety and tolerability were assessed throughout the study, and included monitoring for adverse events, physical examinations, vital signs and clinical laboratory measurements. Investigators evaluated each clinical adverse event for intensity, duration, outcome and relationship to study drug. Adverse events of special interest included hypoglycemia and gastrointestinal symptoms. We also assessed medication compliance at the end of the study by asking patients directly. The study was open-label, but data were masked from the statistician until database release.</p></sec><sec><title>Statistical Analysis</title><p>Based on previous reports<xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref>, the standard deviation was assumed to be 0.6%, and the true difference between the two randomized treatments was zero in HbA1c. We determined that enrolment of 116 patients (58 patients in each group) would provide a power of at least 80% and a significance level of 0.025 (one-sided), to show non-inferiority for sitagliptin, based on the change in HbA1c from baseline to week&#x000a0;12, with a 0.25% HbA1c non-inferiority margin, which we considered to be a clinically acceptable margin<xref rid="b24" ref-type="bibr">24</xref>. Additional assumption in sample-size calculations was that 15% of patients would be lost to follow up. Non-inferiority would be established by the upper limit of the two-sided 95% confidence interval (CI) for treatment difference in the adjusted mean change in HbA1c from baseline to end-point of &#x0003c;0.25% (non-inferiority margin).</p><p>Data collection and all the statistical analyses were independently carried out at the Chiba University Hospital Clinical Research Center, Chiba, Japan. The analyses of the primary and secondary outcomes were carried out on data from all patients who had undergone randomization, according to the intention-to-treat principle.</p><p>For baseline variables, summary statistics were constructed using frequencies and proportions for categorical data, and means and standard deviations for continuous variables. Patient characteristics were compared using Fisher's exact test for categorical outcomes and unpaired <italic>t</italic>-tests with equal variance for continuous variables, as appropriate.</p><p>The primary end-point of change in HbA1c from baseline at week&#x000a0;12 was analyzed by analysis of covariance (<sc>ancova</sc>) with treatment as fixed effect, sex, premedication and age as covariates. As a sensitivity analysis, for dimensional outcomes, linear mixed-effects models were used to determine mean values at each assessment point (12 and 24&#x000a0;weeks), and to test the study hypotheses with respect to between-group differences at 24&#x000a0;weeks. In the linear mixed-effects model, time and treatment were included as fixed effects, and intercept and linear slope terms as random effects, and a compound symmetry covariance was used to account for within-subject correlation over time.</p><p>As with the safety analysis, serious adverse events, anticipated adverse events and adverse events leading to permanent study-drug withdrawal were tabulated according to randomized group assignment, and analyzed by Fisher's exact test.</p><p>All comparisons were planned, and all <italic>P</italic>-values were two-sided. A <italic>P</italic>-value of &#x0003c;0.05 was considered statistically significant. All statistical analyses were carried out using SAS software version 9.3 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Demographics and Baseline Characteristics</title><p>A total of 119 patients were initially screened and randomly assigned to either sitagliptin (<italic>n</italic>&#x000a0;=&#x000a0;60) or &#x003b1;-glucosidase inhibitor (<italic>n</italic>&#x000a0;=&#x000a0;59) in addition to metformin or pioglitazone. A total of 116 (97.5%) received at least one dose of the study drug, and 105 (88.2%) completed the study. Seven patients dropped out from each treatment group during the trial because of withdrawal of consent, adverse events and lost to follow up (Figure<xref ref-type="fig" rid="fig01">1</xref>). Characteristics of patients were well balanced between treatment groups (Table<xref ref-type="table" rid="tbl1">1</xref>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Baseline demographic and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Sitagliptin (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>58)</th><th align="left" rowspan="1" colspan="1">&#x003b1;-Glucosidase inhibitor (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>58)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tf1-1">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">57.6&#x000a0;&#x000b1;&#x000a0;12.9</td><td align="left" rowspan="1" colspan="1">59.3&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" colspan="4" rowspan="1">Sex</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="left" rowspan="1" colspan="1">38 (65.5)</td><td align="left" rowspan="1" colspan="1">36 (62.1)</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="left" rowspan="1" colspan="1">20 (34.5)</td><td align="left" rowspan="1" colspan="1">22 (37.9)</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)</td><td align="left" rowspan="1" colspan="1">1.64&#x000a0;&#x000b1;&#x000a0;0.10</td><td align="left" rowspan="1" colspan="1">1.62&#x000a0;&#x000b1;&#x000a0;0.091</td><td align="left" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">70.2&#x000a0;&#x000b1;&#x000a0;14.2</td><td align="left" rowspan="1" colspan="1">69.8&#x000a0;&#x000b1;&#x000a0;16.3</td><td align="left" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">25.9&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="left" rowspan="1" colspan="1">26.3&#x000a0;&#x000b1;&#x000a0;4.6</td><td align="left" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">132.0&#x000a0;&#x000b1;&#x000a0;13.7</td><td align="left" rowspan="1" colspan="1">132.9&#x000a0;&#x000b1;&#x000a0;14.9</td><td align="left" rowspan="1" colspan="1">0.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">79.9&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="left" rowspan="1" colspan="1">79.5&#x000a0;&#x000b1;&#x000a0;11.0</td><td align="left" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of diabetes (years)</td><td align="left" rowspan="1" colspan="1">6.7&#x000a0;&#x000b1;&#x000a0;6.4</td><td align="left" rowspan="1" colspan="1">6.8&#x000a0;&#x000b1;&#x000a0;5.5</td><td align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="left" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;0.70</td><td align="left" rowspan="1" colspan="1">7.6&#x000a0;&#x000b1;&#x000a0;0.74</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/L)</td><td align="left" rowspan="1" colspan="1">7.7&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left" rowspan="1" colspan="1">7.4&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting C-peptide (mmol/L)</td><td align="left" rowspan="1" colspan="1">0.61&#x000a0;&#x000b1;&#x000a0;0.36</td><td align="left" rowspan="1" colspan="1">0.67&#x000a0;&#x000b1;&#x000a0;0.34</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting insulin (pmol/L)</td><td align="left" rowspan="1" colspan="1">51.6&#x000a0;&#x000b1;&#x000a0;44.2</td><td align="left" rowspan="1" colspan="1">61.5&#x000a0;&#x000b1;&#x000a0;50.7</td><td align="left" rowspan="1" colspan="1">0.27</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-&#x003b2;</td><td align="left" rowspan="1" colspan="1">36.2&#x000a0;&#x000b1;&#x000a0;26.6</td><td align="left" rowspan="1" colspan="1">52.6&#x000a0;&#x000b1;&#x000a0;54.9</td><td align="left" rowspan="1" colspan="1">0.045</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="left" rowspan="1" colspan="1">2.7&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="left" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="left" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" colspan="4" rowspan="1">Fasting lipid profiles</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Total cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">5.0&#x000a0;&#x000b1;&#x000a0;0.88</td><td align="left" rowspan="1" colspan="1">4.9&#x000a0;&#x000b1;&#x000a0;0.88</td><td align="left" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.68</td><td align="left" rowspan="1" colspan="1">2.8&#x000a0;&#x000b1;&#x000a0;0.71</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;HDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.4&#x000a0;&#x000b1;&#x000a0;0.41</td><td align="left" rowspan="1" colspan="1">1.4&#x000a0;&#x000b1;&#x000a0;0.34</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Triglycerides (mmol/L)</td><td align="left" rowspan="1" colspan="1">1.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left" rowspan="1" colspan="1">1.6&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="left" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Non-HDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">3.7&#x000a0;&#x000b1;&#x000a0;0.85</td><td align="left" rowspan="1" colspan="1">3.5&#x000a0;&#x000b1;&#x000a0;0.86</td><td align="left" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" colspan="4" rowspan="1">Prior antidiabetic treatment</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Metformin</td><td align="left" rowspan="1" colspan="1">47 (81.0)</td><td align="left" rowspan="1" colspan="1">46 (79.3)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Pioglitazone</td><td align="left" rowspan="1" colspan="1">11 (19.0)</td><td align="left" rowspan="1" colspan="1">12 (20.7)</td><td align="left" rowspan="1" colspan="1">0.82</td></tr><tr><td align="left" colspan="4" rowspan="1">Concomitant treatments</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antihypertensive drugs</td><td align="left" rowspan="1" colspan="1">29 (50.0)</td><td align="left" rowspan="1" colspan="1">27 (46.6)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antihyperlipemic drugs</td><td align="left" rowspan="1" colspan="1">28 (48.3)</td><td align="left" rowspan="1" colspan="1">26 (44.8)</td><td align="left" rowspan="1" colspan="1">0.71</td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><p>Data are presented as mean&#x000a0;&#x000b1;&#x000a0;standard deviation values, or <italic>n</italic> (%). <sup>*</sup><italic>P</italic>-values for differences between the sitagliptin and &#x003b1;-glucosidase inhibitor groups. BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-&#x003b2;, homoeostasis model assessment of &#x003b2;-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance.</p></fn></table-wrap-foot></table-wrap><fig id="fig01" position="float"><label>Figure 1</label><caption><p>Flow chart of study participants throughout the trial. Data are number of study participants.</p></caption><graphic xlink:href="jdi0006-0182-f1"/></fig></sec><sec><title>Efficacy</title><p>HbA1c was reduced to a significantly greater extent with sitagliptin than with an &#x003b1;-glucosidase inhibitor at weeks&#x000a0;12 and 24 (Figure<xref ref-type="fig" rid="fig02">2</xref>). At week&#x000a0;12, adjusted mean decreases in HbA1c from baseline were &#x02212;0.70% (95% CI &#x02212;0.83 to &#x02212;0.58) for sitagliptin and &#x02212;0.21% (95% CI &#x02212;0.34 to &#x02212;0.097) for the &#x003b1;-glucosidase inhibitors in the full analysis set. The least squares mean of treatment difference was &#x02212;0.49% (&#x02212;0.66 to &#x02212;0.32) (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001). This result met the predefined non-inferiority criterion of 0.25% and after that confirmed the superiority of sitagliptin over &#x003b1;-glucosidase inhibitors. Additionally, at week 24, adjusted mean decreases in HbA1c from baseline were &#x02212;0.71% (95% CI &#x02212;0.88 to &#x02212;0.54) for sitagliptin and &#x02212;0.29% (95% CI &#x02212;0.50 to &#x02212;0.077) for the &#x003b1;-glucosidase inhibitors (difference &#x02212;0.43%, 95% CI &#x02212;0.69 to &#x02212;0.16, <italic>P</italic>&#x000a0;=&#x000a0;0.0024). Treatment difference for the analyses by a linear mixed model was similar to those derived for the analysis of covariance (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001, a mixed-effects model).</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>Changes in glycated hemoglobin (HbA1c) from baseline with the sitagliptin group (black bars) and &#x003b1;-glucosidase inhibitors group (white bars) at week&#x000a0;12 and 24. Error bars represent standard error. *<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 from baseline (sitagliptin group). **<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 from baseline (&#x003b1;-glucosidase inhibitors group). ***<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 between sitagliptin and &#x003b1;-glucosidase inhibitors with the same week.</p></caption><graphic xlink:href="jdi0006-0182-f2"/></fig><p>Throughout the study, significantly more participants achieved HbA1c targets &#x0003c;7.0% with sitagliptin combination therapy than with &#x003b1;-glucosidase inhibitor combination therapy. At week&#x000a0;12, 31 (55.3%) of 56 participants receiving sitagliptin combination therapy had a HbA1c &#x0003c;7.0% compared with 17 (32.1%) of 53 receiving &#x003b1;-glucosidase inhibitor combination therapy (<italic>P</italic>&#x000a0;=&#x000a0;0.0089). Similarly, at week&#x000a0;24, 32 (60.0%) of 53 participants on sitagliptin combination therapy had a HbA1c &#x0003c;7.0% compared with 17 (32.7%) of 52 receiving &#x003b1;-glucosidase inhibitor combination therapy (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.0020).</p><p>Treatment with sitagliptin also led to a significant decrease in FPG from baseline at week&#x000a0;12 and 24 (Table<xref ref-type="table" rid="tbl2">2</xref>). The least squares mean of treatment difference in FPG at week&#x000a0;12 was &#x02212;0.86&#x000a0;mmol/L (95% CI &#x02212;1.5 to &#x02212;0.21) lower with sitagliptin than with &#x003b1;-glucosidase inhibitors (<italic>P&#x000a0;</italic>=<italic>&#x000a0;</italic>0.010), but no significant difference was noted at week&#x000a0;24. The analyses limited to the patients who had been taking metformin also led to the same results regarding glucose-lowering effects (data not shown).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Change in secondary endpoints from baseline to weeks&#x000a0;12 and 24</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="char" colspan="3" rowspan="1">Mean change from baseline (week&#x000a0;12)</th><th align="char" colspan="3" rowspan="1">Mean change from baseline (week&#x000a0;24)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Sitagliptin</th><th align="left" rowspan="1" colspan="1">&#x003b1;-Glucosidase inhibitor</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tf2-2">*</xref></th><th align="left" rowspan="1" colspan="1">Sitagliptin</th><th align="left" rowspan="1" colspan="1">&#x003b1;-Glucosidase inhibitor</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tf2-2">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Glycoalbumin (%)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;2.9 to &#x02212;2.0)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.74 (&#x02212;1.2 to &#x02212;0.29)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="left" rowspan="1" colspan="1">&#x02212;2.5 (&#x02212;3.0 to &#x02212;1.9)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.1 (&#x02212;1.8 to &#x02212;0.31)</td><td align="left" rowspan="1" colspan="1">0.0026</td></tr><tr><td align="left" rowspan="1" colspan="1">1,5-AG (&#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1">21.6 (16.7 to 26.5)</td><td align="left" rowspan="1" colspan="1">28.9 (21.9 to 35.9)</td><td align="left" rowspan="1" colspan="1">0.089</td><td align="left" rowspan="1" colspan="1">23.2 (16.8 to 29.6)</td><td align="left" rowspan="1" colspan="1">32.6 (24.5 to 40.8)</td><td align="left" rowspan="1" colspan="1">0.072</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/L)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.60 (&#x02212;1.1 to &#x02212;0.092)</td><td align="left" rowspan="1" colspan="1">0.26 (&#x02212;0.16 to 0.68)</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">&#x02212;0.54 (&#x02212;1.0 to &#x02212;0.066)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.15 (&#x02212;0.60 to 0.29)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting insulin (pmol/L)</td><td align="left" rowspan="1" colspan="1">6.7 (&#x02212;5.7 to 18.9)</td><td align="left" rowspan="1" colspan="1">5.6 (&#x02212;9.4 to 20.6)</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0088 (&#x02212;10.6 to 10.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;3.4 (&#x02212;15.0 to 8.3)</td><td align="left" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting C-peptide (nmol/L)</td><td align="left" rowspan="1" colspan="1">0.061 (&#x02212;0.033 to 0.15)</td><td align="left" rowspan="1" colspan="1">0.032 (&#x02212;0.061 to 0.13)</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">0.041 (&#x02212;0.042 to 0.12)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.010 (&#x02212;0.082 to 0.61)</td><td align="left" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting proinsulin-to-insulin ratio</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0057 (&#x02212;0.068 to 0.056)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.031 (&#x02212;0.086 to 0.025)</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">&#x02212;0.041 (&#x02212;0.11 to 0.027)</td><td align="left" rowspan="1" colspan="1">0.028 (&#x02212;0.043 to 0.10)</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-&#x003b2;</td><td align="left" rowspan="1" colspan="1">10.8 (6.0 to 15.6)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;16.2 to 11.4)</td><td align="left" rowspan="1" colspan="1">0.072</td><td align="left" rowspan="1" colspan="1">8.9 (2.7 to 15.2)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.60 (&#x02212;9.2 to 8.0)</td><td align="left" rowspan="1" colspan="1">0.078</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0094 (&#x02212;1.0 to 1.0)</td><td align="left" rowspan="1" colspan="1">0.57 (&#x02212;0.32 to 1.5)</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">&#x02212;0.38 (&#x02212;1.4 to 0.64)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.12 (&#x02212;0.91 to 0.67)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Bodyweight (kg)</td><td align="left" rowspan="1" colspan="1">0.25 (&#x02212;0.12 to 0.62)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.39 (&#x02212;0.68 to &#x02212;0.093)</td><td align="left" rowspan="1" colspan="1">0.0079</td><td align="left" rowspan="1" colspan="1">0.47 (&#x02212;0.041 to 0.99)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.60 (&#x02212;1.0 to &#x02212;0.16)</td><td align="left" rowspan="1" colspan="1">0.0021</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">1.4 (&#x02212;2.2 to 5.1)</td><td align="left" rowspan="1" colspan="1">1.0 (&#x02212;1.8 to 3.9)</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">1.6 (&#x02212;1.9 to 5.0)</td><td align="left" rowspan="1" colspan="1">0.059 (&#x02212;3.7 to 3.8)</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.47 (&#x02212;2.6 to 1.7)</td><td align="left" rowspan="1" colspan="1">0.67 (&#x02212;1.9 to 3.2)</td><td align="left" rowspan="1" colspan="1">0.49</td><td align="left" rowspan="1" colspan="1">&#x02212;0.38 (&#x02212;2.2 to 1.4)</td><td align="left" rowspan="1" colspan="1">0.80 (&#x02212;2.8 to 4.4)</td><td align="left" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart rate (beats per min)</td><td align="left" rowspan="1" colspan="1">1.5 (&#x02212;1.2 to 4.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;1.9 (&#x02212;4.0 to 0.30)</td><td align="left" rowspan="1" colspan="1">0.054</td><td align="left" rowspan="1" colspan="1">0.67 (&#x02212;2.0 to 3.3)</td><td align="left" rowspan="1" colspan="1">&#x02212;2.4 (&#x02212;5.3 to 0.56)</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.35 to 0.087)</td><td align="left" rowspan="1" colspan="1">0.21 (0.065 to 0.36)</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">&#x02212;0.11 (&#x02212;0.34 to 0.11)</td><td align="left" rowspan="1" colspan="1">0.18 (0.044 to 0.32)</td><td align="left" rowspan="1" colspan="1">0.025</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">0.0066 (&#x02212;0.15 to 0.16)</td><td align="left" rowspan="1" colspan="1">0.21 (0.077 to 0.35)</td><td align="left" rowspan="1" colspan="1">0.047</td><td align="left" rowspan="1" colspan="1">&#x02212;0.013 (&#x02212;0.19 to 0.16)</td><td align="left" rowspan="1" colspan="1">0.19 (0.060 to 0.31)</td><td align="left" rowspan="1" colspan="1">0.065</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0024 (&#x02212;0.044 to 0.039)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.012 (&#x02212;0.058 to 0.034)</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.025 (&#x02212;0.33 to 0.084)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.0025 (&#x02212;0.047 to 0.042)</td><td align="left" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.050 (&#x02212;0.28 to 0.18)</td><td align="left" rowspan="1" colspan="1">0.010 (&#x02212;0.18 to 0.20)</td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">&#x02212;0.11 (&#x02212;0.37 to 0.15)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.17 (&#x02212;0.34 to &#x02212;0.0076)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Non-HDL cholesterol (mmol/L)</td><td align="left" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.34 to 0.078)</td><td align="left" rowspan="1" colspan="1">0.22 (0.090 to 0.36)</td><td align="left" rowspan="1" colspan="1">0.0050</td><td align="left" rowspan="1" colspan="1">&#x02212;0.13 (&#x02212;0.35 to 0.093)</td><td align="left" rowspan="1" colspan="1">0.18 (0.051 to 0.32)</td><td align="left" rowspan="1" colspan="1">0.015</td></tr></tbody></table><table-wrap-foot><fn id="tf2-1"><p>Changes from baseline to week&#x000a0;12 or week&#x000a0;24 are expressed as least-squares mean change (95% confidence interval).</p></fn><fn id="tf2-2"><label>*</label><p><italic>P</italic>-value was calculated by comparing the difference from baseline between the sitagliptin and &#x003b1;-glucosidase inhibitor groups. HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-&#x003b2;, homoeostasis model assessment of &#x003b2;-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance.</p></fn></table-wrap-foot></table-wrap><p>Changes in other secondary end-points are summarized in Table<xref ref-type="table" rid="tbl2">2</xref> and <xref ref-type="supplementary-material" rid="sd1">Table S1</xref>. In addition to HbA1c, glycoalbumin was reduced to a significantly greater extent with sitagliptin than with &#x003b1;-glucosidase inhibitors throughout the study. 1,5-AG levels significantly increased from baseline in both groups, but differences between groups were not significant. Sitagliptin significantly improved HOMA-&#x003b2; values from baseline, but no significant differences were observed between groups. For other glycemic efficacy parameters, no notable differences were seen in either treatment group.</p><p>While sitagliptin did not affect bodyweight, &#x003b1;-glucosidase inhibitors decreased bodyweight significantly from baseline (Table<xref ref-type="table" rid="tbl2">2</xref>). The adjusted mean differences were 0.64&#x000a0;kg (95% CI 0.17&#x02013;1.1, <italic>P</italic>&#x000a0;=&#x000a0;0.0079) at week&#x000a0;12, and 1.1&#x000a0;kg (0.40&#x02013;1.7; <italic>P</italic>&#x000a0;=&#x000a0;0.0021) at week&#x000a0;24 between two groups. As with the glucose-lowering effects, the analyses limited to the patients who had been taking metformin also showed the same significant differences in bodyweight (data not shown).</p><p>No clinically meaningful changes in blood pressure and heart rate were observed in either group. Sitagliptin also had no effects on serum lipid parameters, whereas &#x003b1;-glucosidase inhibitors increased the levels of total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein&#x000a0;B (<xref ref-type="supplementary-material" rid="sd1">Table&#x000a0;S1</xref>), which led to the significant differences between the two groups.</p></sec><sec><title>Safety</title><p>Table<xref ref-type="table" rid="tbl3">3</xref> summarizes treatment-emergent adverse events. Adverse events were reported by 19 (32.8%) of 58 participants in the sitagliptin group, and 30 (51.7%) of 58 participants in the &#x003b1;-glucosidase inhibitor group. One (1.7%) serious treatment-emergent adverse event was observed in each group (ileus and cholangitis); no deaths occurred. Two (3.5%) episodes of mild hypoglycemia occurred in each group. The most common adverse events were gastrointestinal symptoms, and the incidence was significantly greater with the &#x003b1;-glucosidase inhibitors (23 [39.7%]) than with sitagliptin (6 [10.3%]). Each of the prespecified gastrointestinal adverse events (diarrhea, flatulence, abdominal distention) was also significantly greater with the &#x003b1;-glucosidase inhibitors than with sitagliptin. Two (3.5%) of 58 participants in the sitagliptin group and five (8.6%) of 58 participants in the &#x003b1;-glucosidase inhibitor group withdrew from the study because of a treatment-emergent adverse event. Withdrawals in the sitagliptin group were as a result of edema and cholangitis, whereas withdrawals in the &#x003b1;-glucosidase inhibitor group were as a result of ileus, diarrhea, flatulence, abdominal distention and ear pain. Other main adverse events included the common cold, dizziness and headache. The incidence of these adverse events was &#x0003c;5%. Laboratory variables did not show any clinically significant findings. Medication compliance was lower with the &#x003b1;-glucosidase inhibitor than with sitagliptin (88.2% vs 98.0%; <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.0001).</p><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>Adverse events observed</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Sitagliptin (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>58)</th><th align="left" rowspan="1" colspan="1">&#x003b1;-Glucosidase inhibitor (<italic>n&#x000a0;</italic>=<italic>&#x000a0;</italic>58)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value<xref ref-type="table-fn" rid="tf3-2">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Any adverse event</td><td align="left" rowspan="1" colspan="1">19 (32.8)</td><td align="left" rowspan="1" colspan="1">30 (51.7)</td><td align="left" rowspan="1" colspan="1">0.0039</td></tr><tr><td align="left" rowspan="1" colspan="1">Serious adverse events</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Drug-related adverse events</td><td align="left" rowspan="1" colspan="1">4 (6.9)</td><td align="left" rowspan="1" colspan="1">19 (32.8)</td><td align="left" rowspan="1" colspan="1">0.00050</td></tr><tr><td align="left" rowspan="1" colspan="1">Adverse events leading to discontinuation</td><td align="left" rowspan="1" colspan="1">2 (3.5)</td><td align="left" rowspan="1" colspan="1">5 (8.6)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Deaths</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" colspan="4" rowspan="1">Adverse events of special interest</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypoglycemia</td><td align="left" rowspan="1" colspan="1">2 (3.5)</td><td align="left" rowspan="1" colspan="1">2 (3.5)</td><td align="left" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Gastrointestinal disorders</td><td align="left" rowspan="1" colspan="1">6 (10.3)</td><td align="left" rowspan="1" colspan="1">23 (39.7)</td><td align="left" rowspan="1" colspan="1">0.00030</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Diarrhea</td><td align="left" rowspan="1" colspan="1">2 (3.5)</td><td align="left" rowspan="1" colspan="1">11 (19.0)</td><td align="left" rowspan="1" colspan="1">0.0081</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Flatulence</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">10 (17.2)</td><td align="left" rowspan="1" colspan="1">0.039</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Abdominal distention</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">10 (17.2)</td><td align="left" rowspan="1" colspan="1">0.0043</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Nausea</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Constipation</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Abdominal pain</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">3 (5.2)</td><td align="left" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Loss of appetite</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1 (1.7)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr></tbody></table><table-wrap-foot><fn id="tf3-1"><p>Data are presented as <italic>n</italic> (%).</p></fn><fn id="tf3-2"><label>*</label><p><italic>P</italic>-values for differences between the sitagliptin and &#x003b1;-glucosidase inhibitor groups after 24&#x000a0;weeks of treatment.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The results of the present study showed that in Japanese patients with type&#x000a0;2 diabetes inadequately controlled by metformin or pioglitazone, sitagliptin, a DPP-4 inhibitor, was not only non-inferior, but also superior to the &#x003b1;-glucosidase inhibitor for lowering HbA1c from baseline (on the same level with previous Japanese report compared with placebo<xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref>). In addition, more than half of the patients receiving sitagliptin achieved the current ADA glycemic goal of HbA1c &#x0003c;7.0%<xref rid="b26" ref-type="bibr">26</xref>.</p><p>In parallel to the present study, we also carried out a trial in type&#x000a0;2 diabetes to assess the efficacy and safety of sitagliptin compared with &#x003b1;-glucosidase inhibitor in combination with sulfonylurea (SUCCESS-2 study)<xref rid="b29" ref-type="bibr">29</xref>. In the SUCCESS-2 study, sitagliptin was not only non-inferior, but also superior to &#x003b1;-glucosidase for reduction of HbA1c at 12&#x000a0;weeks, but remained non-inferior at 24&#x000a0;weeks. The results of SUCCESS-1 and 2 together showed that combination of sitagliptin with insulin-sensitizing agents might be adequate for glucose lowering at least within a 24-week period.</p><p>The reasons why the combination of sitagliptin with metformin or pioglitazone was better than with &#x003b1;-glucosidase inhibitor might depend on the levels of incretin hormones. Metformin has been reported to increase the plasma level of glucagon-like peptide-1 (GLP-1) and enhance the expression of the genes encoding the receptors for incretin hormones in mouse islets<xref rid="b30" ref-type="bibr">30</xref>. In line with the finding, an addition of sitagliptin to metformin therapy showed a complementary effect on active GLP-1 concentrations<xref rid="b31" ref-type="bibr">31</xref>. In contrast, in obese patients, pioglitazone shifts fat distribution from visceral to subcutaneous adipose depots<xref rid="b32" ref-type="bibr">32</xref>, and DPP-4 protein expression in visceral fat is higher than subcutaneous fat<xref rid="b33" ref-type="bibr">33</xref>. These findings suggest that sitagliptin, in combination with pioglitazone, might synergistically increase incretin levels in patients with type&#x000a0;2 diabetes.</p><p>Although metformin and pioglitazone are classified as insulin-sensitizing agents, their action mechanism is different from each other. In the present study, the number of patients receiving pioglitazone monotherapy was too small to evaluate its precise effects. For that reason, we carried out statistical analyses limited to the patients who had been taking metformin, and confirmed that the effects on glucose-lowering and bodyweight were the same as all the participants.</p><p>In contrast, &#x003b1;-glucosidase inhibitor also increases active GLP-1, but it decreases gastric inhibitory polypeptide (GIP) and postprandial serum insulin<xref rid="b34" ref-type="bibr">34</xref>,<xref rid="b35" ref-type="bibr">35</xref>. It is inferred that these changes of incretin and insulin secretion after meals had occurred in the &#x003b1;-glucosidase inhibitor group.</p><p>Both sitagliptin and &#x003b1;-glucosidase inhibitor are known to lower postprandial blood glucose levels; we found that these drugs also significantly increased 1,5-AG levels from baseline, a marker reflecting postprandial blood glucose levels<xref rid="b36" ref-type="bibr">36</xref>. In contrast, only sitagliptin significantly decreased FPG levels from baseline with no changes in fasting insulin concentrations or HOMA-IR. These results might show that sitagliptin combined with insulin sensitizer improved not only postprandial hyperglycemia through glucose-dependent insulin secretion, but also inhibiting hepatic glucose production<xref rid="b37" ref-type="bibr">37</xref>. Sitagliptin is known to suppress paradoxical glucagon secretion in patients with type&#x000a0;2 diabetes as well<xref rid="b38" ref-type="bibr">38</xref>. In the present study, there were no differences in the fasting plasma glucagon levels in both groups. This result leads to our presumption that sitagliptin decreased the postprandial plasma glucagon level more than &#x003b1;-glucosidase inhibitor did.</p><p>It is reported that DPP-4 inhibitors have a potential to protect pancreatic islet cells<xref rid="b39" ref-type="bibr">39</xref>,<xref rid="b40" ref-type="bibr">40</xref>, and are expected to decrease cardiovascular risk in type&#x000a0;2 diabetes<xref rid="b41" ref-type="bibr">41</xref>. These findings also give us a rationale and further insights to use sitagliptin in combination with metformin or pioglitazone.</p><p>In contrast, &#x003b1;-glucosidase inhibitors significantly decreased bodyweight in the present study. This could have been as a result of a reduction of postprandial insulin secretion, changes in incretin hormone profiles (e.g., increase in active GLP-1 and decrease in GIP)<xref rid="b34" ref-type="bibr">34</xref>,<xref rid="b35" ref-type="bibr">35</xref>, enhancing sensations of satiety<xref rid="b42" ref-type="bibr">42</xref> and energy expenditure<xref rid="b43" ref-type="bibr">43</xref>. These effects of &#x003b1;-glucosidase inhibitor-related incretin secretion seem to be prominent in voglibose and miglitol rather than acarbose<xref rid="b44" ref-type="bibr">44</xref>, and in not elderly patients<xref rid="b45" ref-type="bibr">45</xref>. The present results show a potential benefit of &#x003b1;-glucosidase inhibitors in treating obese and middle-aged patients with type&#x000a0;2 diabetes.</p><p>Although some studies<xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b24" ref-type="bibr">24</xref>,<xref rid="b46" ref-type="bibr">46</xref> have shown that blood pressure or lipid profiles (total cholesterol, high-density lipoprotein cholesterol and triglycerides) are improved with sitagliptin, no significant changes in these parameters were seen in the present study. When the present study started, nearly half of the patients had already been taking antihypertensive or antihyperlipidemic drugs, and their blood pressure and lipid profiles had been in relatively good control (Table<xref ref-type="table" rid="tbl1">1</xref>). So in our study, the effects on blood pressure and lipid profiles by sitagliptin might have been attenuated. The reasons why &#x003b1;-glucosidase inhibitor increased the levels of lipid parameters in this study remains to be elucidated.</p><p>As reported previously<xref rid="b12" ref-type="bibr">12</xref>&#x02013;<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b21" ref-type="bibr">21</xref>&#x02013;<xref rid="b24" ref-type="bibr">24</xref>,<xref rid="b27" ref-type="bibr">27</xref>,<xref rid="b28" ref-type="bibr">28</xref>, sitagliptin was well tolerated, with a small increase in the risk of gastrointestinal disorders and hypoglycemia. In contrast, we observed a higher frequency of gastrointestinal disorders and lower medication compliance during treatment with an &#x003b1;-glucosidase inhibitor.</p><p>There were some potential limitations to the present study. First, the number of participants enrolled was small, and the treatment period of 24&#x000a0;weeks might have been too short. Second, this study included possible selection bias. Also, the present study was open-label trial, but the primary end-point HbA1c was a hard end-point and other measures were put in place in order to minimize the potential for bias. Third, we only examined fasting parameters. Further studies are required with a large number, longer follow-up period and taking into account postprandial parameters.</p><p>In conclusion, we showed that sitagliptin, compared with &#x003b1;-glucosidase inhibitors, provided greater glycemic control and better tolerability with significantly lower gastrointestinal symptoms and higher medication compliance when used in combination with metformin or pioglitazone in Japanese patients with type&#x000a0;2 diabetes. Our findings support the use of sitagliptin in combination with metformin or pioglitazone in Japanese patients with type&#x000a0;2 diabetes.</p></sec></body><back><ack><p>This study was designed and led by a steering committee of the SUCCESS study group, funded by the Waksman Foundation of Japan Inc., Tokyo, the Grant-in-Aid from the Japanese Ministry of Health, Labor and Welfare, and the Ministry of Education, Culture, Sports, Science and Technology. KY has received research endowment for his Department from MSD (Merck). The sponsors played no role in the design and management of the study, collection and analysis of the data, interpretation of the results, or the writing of the report. The authors declare no conflict of interest. The authors thank the SUCCESS investigators for participating in this study (see the list of investigators in Appendix&#x000a0;1) and the staff of the Chiba University Hospital Clinical Research Center for their assistance in the performance of this study: Junpei Kamimoto, Ami Kuninobu, Ayumi Miura, Yumiko Imai, Asako Kohno, Nanae Tanemura, Asuka Nemoto, Nobuko Yamaguchi and Yasuhisa Fujii.</p></ack><ref-list><title>References</title><ref id="b1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>DR</given-names></name><name><surname>Guariguata</surname><given-names>L</given-names></name><name><surname>Weil</surname><given-names>C</given-names></name><etal/></person-group><article-title>IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>94</volume><fpage>311</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">22079683</pub-id></element-citation></ref><ref id="b2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohkubo</surname><given-names>Y</given-names></name><name><surname>Kishikawa</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study</article-title><source>Diabetes Res Clin Pract</source><year>1995</year><volume>28</volume><fpage>103</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">7587918</pub-id></element-citation></ref><ref id="b3"><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab><article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type&#x000a0;2 diabetes (UKPDS 33)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">9742976</pub-id></element-citation></ref><ref id="b4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><etal/></person-group><article-title>10-year follow-up of intensive glucose control in type&#x000a0;2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="b5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyler</surname><given-names>JS</given-names></name><name><surname>Bergenstal</surname><given-names>R</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><etal/></person-group><article-title>Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">19095622</pub-id></element-citation></ref><ref id="b6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type&#x000a0;2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>1364</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">22517736</pub-id></element-citation></ref><ref id="b7"><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab><article-title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type&#x000a0;2 diabetes (UKPDS 34)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">9742977</pub-id></element-citation></ref><ref id="b8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name></person-group><article-title>Thiazolidinediones</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>1106</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">15356308</pub-id></element-citation></ref><ref id="b9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Eckland</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Secondary prevention of macrovascular events in patients with type&#x000a0;2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1279</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">16214598</pub-id></element-citation></ref><ref id="b10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>RC</given-names></name><name><surname>Cull</surname><given-names>CA</given-names></name><name><surname>Frighi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type&#x000a0;2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group</article-title><source>JAMA</source><year>1999</year><volume>281</volume><fpage>2005</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">10359389</pub-id></element-citation></ref><ref id="b11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Nauck</surname><given-names>MA</given-names></name></person-group><article-title>The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type&#x000a0;2 diabetes</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1696</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">17098089</pub-id></element-citation></ref><ref id="b12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type&#x000a0;2 diabetes mellitus</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2564</fpage><lpage>2571</lpage><pub-id pub-id-type="pmid">17001471</pub-id></element-citation></ref><ref id="b13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschner</surname><given-names>P</given-names></name><name><surname>Kipnes</surname><given-names>MS</given-names></name><name><surname>Lunceford</surname><given-names>JK</given-names></name><etal/></person-group><article-title>Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type&#x000a0;2 diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2632</fpage><lpage>2637</lpage><pub-id pub-id-type="pmid">17130196</pub-id></element-citation></ref><ref id="b14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Kakikawa</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin monotherapy in Japanese patients with type&#x000a0;2 diabetes</article-title><source>Diabetes Res Clin Pract</source><year>2008</year><volume>79</volume><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">17933414</pub-id></element-citation></ref><ref id="b15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanatsuka</surname><given-names>A</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><etal/></person-group><article-title>Research on antihyperglycemic drug therapies in patients with type&#x000a0;2 diabetes mellitus in Japan (1): drug therapies and actual drug use</article-title><source>J Jpn Diabetes Soc</source><year>2006</year><volume>49</volume><fpage>409</fpage><lpage>915</lpage></element-citation></ref><ref id="b16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Laar</surname><given-names>FA</given-names></name><name><surname>Lucassen</surname><given-names>PL</given-names></name><name><surname>Akkermans</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Alpha-glucosidase inhibitors for patients with type&#x000a0;2 diabetes: results from a Cochrane systematic review and meta-analysis</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><fpage>154</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">15616251</pub-id></element-citation></ref><ref id="b17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Cagatay</surname><given-names>M</given-names></name><name><surname>Petrowitsch</surname><given-names>T</given-names></name><etal/></person-group><article-title>Acarbose reduces the risk for myocardial infarction in type&#x000a0;2 diabetic patients: meta-analysis of seven long-term studies</article-title><source>Eur Heart J</source><year>2004</year><volume>25</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">14683737</pub-id></element-citation></ref><ref id="b18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">12876091</pub-id></element-citation></ref><ref id="b19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Acarbose for prevention of type&#x000a0;2 diabetes mellitus: the STOP-NIDDM randomised trial</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>2072</fpage><lpage>2077</lpage><pub-id pub-id-type="pmid">12086760</pub-id></element-citation></ref><ref id="b20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamori</surname><given-names>R</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Iwamoto</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Voglibose for prevention of type&#x000a0;2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance</article-title><source>Lancet</source><year>2009</year><volume>373</volume><fpage>1607</fpage><lpage>1614</lpage><pub-id pub-id-type="pmid">19395079</pub-id></element-citation></ref><ref id="b21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>Y</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type&#x000a0;2 diabetes: a randomized, double-blind trial</article-title><source>Diabetes Obes Metab</source><year>2010</year><volume>12</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="pmid">20590736</pub-id></element-citation></ref><ref id="b22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Karasik</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type&#x000a0;2 diabetes inadequately controlled with metformin alone</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2638</fpage><lpage>2643</lpage><pub-id pub-id-type="pmid">17130197</pub-id></element-citation></ref><ref id="b23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Brazg</surname><given-names>R</given-names></name><name><surname>Andryuk</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type&#x000a0;2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study</article-title><source>Clin Ther</source><year>2006</year><volume>28</volume><fpage>1556</fpage><lpage>1568</lpage><pub-id pub-id-type="pmid">17157112</pub-id></element-citation></ref><ref id="b24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratley</surname><given-names>RE</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Bailey</surname><given-names>T</given-names></name><etal/></person-group><article-title>Liraglutide versus sitagliptin for patients with type&#x000a0;2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>1447</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">20417856</pub-id></element-citation></ref><ref id="b25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name></person-group><article-title>Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial</article-title><source>Biometrics</source><year>1975</year><volume>31</volume><fpage>103</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">1100130</pub-id></element-citation></ref><ref id="b26"><element-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>Standards of medical care in diabetes&#x02013;2011</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>Suppl. 1</issue><fpage>S11</fpage><lpage>S61</lpage><pub-id pub-id-type="pmid">21193625</pub-id></element-citation></ref><ref id="b27"><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Odawara</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><comment><italic>Proceedings of the 68th ADA Scientific Sessions</italic> San Francisco, CA Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type&#x000a0;2 diabetes. Abstract Number: 2135-PO</comment></element-citation></ref><ref id="b28"><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>A</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name><etal/></person-group><year>2008</year><comment><italic>Proceedings of the 68th ADA Scientific Sessions</italic> San Francisco, CA Sitagliptin added to ongoing treatment with pioglitazone improved glycemic control and was well tolerated in Japanese patients with type&#x000a0;2 diabetes. Abstract Number: 2136-PO</comment></element-citation></ref><ref id="b29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Yokoh</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with &#x003b1;-glucosidase inhibitor in Japanese patients with type&#x000a0;2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial</article-title><source>Diabetes Obes Metab</source><year>2014</year><volume>16</volume><fpage>761</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">24447683</pub-id></element-citation></ref><ref id="b30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maida</surname><given-names>A</given-names></name><name><surname>Lamont</surname><given-names>BJ</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><etal/></person-group><article-title>Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-&#x003b1; in mice</article-title><source>Diabetologia</source><year>2011</year><volume>54</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">20972533</pub-id></element-citation></ref><ref id="b31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migoya</surname><given-names>EM</given-names></name><name><surname>Bergeron</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1</article-title><source>Clin Pharmacol Ther</source><year>2010</year><volume>88</volume><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">21048706</pub-id></element-citation></ref><ref id="b32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyazaki</surname><given-names>Y</given-names></name><name><surname>Mahankali</surname><given-names>A</given-names></name><name><surname>Matsuda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type&#x000a0;2 diabetic patients</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>2784</fpage><lpage>2791</lpage><pub-id pub-id-type="pmid">12050251</pub-id></element-citation></ref><ref id="b33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>D</given-names></name><name><surname>Famulla</surname><given-names>S</given-names></name><name><surname>Wronkowitz</surname><given-names>N</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><fpage>1917</fpage><lpage>1925</lpage><pub-id pub-id-type="pmid">21593202</pub-id></element-citation></ref><ref id="b34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>T</given-names></name><name><surname>Katsuura</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><etal/></person-group><article-title>Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients</article-title><source>Diabet Med</source><year>2009</year><volume>26</volume><fpage>187</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">19236625</pub-id></element-citation></ref><ref id="b35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narita</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type&#x000a0;2 diabetic patients</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><fpage>283</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">22051162</pub-id></element-citation></ref><ref id="b36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>N</given-names></name><name><surname>Tagaya</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical usefulness of serum 1,5-anhydroglucitol in monitoring glycaemic control</article-title><source>Lancet</source><year>1996</year><volume>347</volume><fpage>1514</fpage><lpage>1518</lpage><pub-id pub-id-type="pmid">8684103</pub-id></element-citation></ref><ref id="b37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solis-Herrera</surname><given-names>C</given-names></name><name><surname>Triplitt</surname><given-names>C</given-names></name><name><surname>Garduno-Garcia</surname><given-names>JeJ</given-names></name><etal/></person-group><article-title>Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>2756</fpage><lpage>2762</lpage><pub-id pub-id-type="pmid">23579178</pub-id></element-citation></ref><ref id="b38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>GA</given-names></name><name><surname>Bergman</surname><given-names>A</given-names></name><name><surname>Stevens</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type&#x000a0;2 diabetes</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>4612</fpage><lpage>4619</lpage><pub-id pub-id-type="pmid">16912128</pub-id></element-citation></ref><ref id="b39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pospisilik</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Doty</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>741</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">12606516</pub-id></element-citation></ref><ref id="b40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name><name><surname>Winzell</surname><given-names>MS</given-names></name><name><surname>Wierup</surname><given-names>N</given-names></name><etal/></person-group><article-title>DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide</article-title><source>Regul Pept</source><year>2007</year><volume>143</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">17482289</pub-id></element-citation></ref><ref id="b41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patil</surname><given-names>HR</given-names></name><name><surname>Al Badarin</surname><given-names>FJ</given-names></name><name><surname>Al Shami</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type&#x000a0;2 diabetes mellitus</article-title><source>Am J Cardiol</source><year>2012</year><volume>110</volume><fpage>826</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">22703861</pub-id></element-citation></ref><ref id="b42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Patrick</surname><given-names>P</given-names></name><name><surname>Wishart</surname><given-names>J</given-names></name><etal/></person-group><article-title>The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type&#x000a0;2 diabetics</article-title><source>Diabetes Obes Metab</source><year>2002</year><volume>4</volume><fpage>329</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">12190996</pub-id></element-citation></ref><ref id="b43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Shimpuku</surname><given-names>M</given-names></name><name><surname>Kitazumi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Miglitol prevents diet-induced obesity by stimulating brown adipose tissue and energy expenditure independent of preventing the digestion of carbohydrates</article-title><source>Endocr J</source><year>2013</year><volume>60</volume><fpage>1117</fpage><lpage>1129</lpage><pub-id pub-id-type="pmid">23995917</pub-id></element-citation></ref><ref id="b44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hucking</surname><given-names>K</given-names></name><name><surname>Kostic</surname><given-names>Z</given-names></name><name><surname>Pox</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients</article-title><source>Diabet Med</source><year>2005</year><volume>22</volume><fpage>470</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">15787675</pub-id></element-citation></ref><ref id="b45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeLeon</surname><given-names>MJ</given-names></name><name><surname>Chandurkar</surname><given-names>V</given-names></name><name><surname>Albert</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 response to acarbose in elderly type&#x000a0;2 diabetic subjects</article-title><source>Diabetes Res Clin Pract</source><year>2002</year><volume>56</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">11891017</pub-id></element-citation></ref><ref id="b46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname><given-names>ES</given-names></name><name><surname>Silberman</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type&#x000a0;2 diabetes receiving incretin therapies or insulin in a large cohort database</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>1759</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">20460445</pub-id></element-citation></ref></ref-list><app-group><app id="app1"><title>Appendix 1</title><sec><title>List of investigators</title><p>Tokuyoshi An, Hirotake Tokuyama, Hideaki Bujyo, Harukiyo Kawamura, Takahisa Shibata, Ichiro Tatsuno, Takayuki Ishibashi, Susumu Nakamura, Keiji Mikami, Kazuo Yamamoto, Kenichi Yamada, Yusuke Hirota, Naoko Tadokoro, Takahiko Tokuyama, Ryoichi Ishibashi, Shin Nakamura, Jun Tashiro, Kyohei Yamamoto, Toshiaki Ban, Rie Sano, Hiroko Ito, Tomoaki Tanaka, Sawako Nishimura, Keiko Saito, Motonobu Nishimura, Masami Fuse, Masahiro Mimura, Sawako Suzuki, Kaori Tachibana, Masahiko Yamada, Takahiro Ishikawa, Miwako Nakamura, Tsuyoshi Oji, Masaki Fujimoto, Kazuki Kobayashi, Hidetaka Yokoh, Yasunori Sato, Minoru Takemoto, Daigaku Uchida, Azuma Kanatsuka, Nobuichi Kuribayashi, Takashi Terano, Naotake Hashimoto, Kenichi Sakurai, Hideki Hanaoka, Ko Ishikawa, Shunichiro Onishi and Koutaro Yokote.</p></sec></app></app-group><sec sec-type="supplementary-material"><title>Supporting Information</title><supplementary-material content-type="local-data" id="sd1"><p><bold>Table S1</bold> | Changes in secondary end-points from baseline to week 12 and 24.</p><media mimetype="doc" mime-subtype="doc" xlink:href="jdi0006-0182-sd1.doc" xlink:type="simple" id="d35e2856" position="anchor"/></supplementary-material></sec></back></article>